UK FSHD patient registry publishes overview of ongoing clinical trials

Ben Porter, curator of the UK FSHD Patient Registry, has published a visual overview of ongoing clinical trials for FSHD (type 1 and 2) worldwide. In addition to the already known Fulcrum Therapeutics trial, which is in clinical phase 2 and whose first results are expected in the middle of the year, you will also find a number of promising gene and other therapies from various companies (e.g. Dyne Therapeutics, miRecule Inc., Myocea Inc., Facio Therapies) and research institutes (e.g. Nationwide Children’s Hospital, King’s College London). If you want to know more about a specific study, you can click on the links provided in the last column.